Andrew Bowser
Oral baricitinib instead of topicals for atopic dermatitis?
EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV Congress
IL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.
Look beyond diagnosis to see beauty and humanity
Look beyond diagnosis to see beauty and humanity
As the 26th European Academy of Dermatology and Venereology Congress opens this week in Geneva, meeting attendees were treated to a talk by medical photographer Rick Guidotti.
Do we need pigment to develop melanoma?
Do we need pigment to develop melanoma?
New insights into the pigment pathway are improving the understanding of how immunotherapy works in melanoma.
Atopic dermatitis associated with different bacteria depending on disease severity
NIH investigators find that Staphylococcus epidermidis is predominant in less severe cases, while Staphylococcus aureus is associated with patients who have more severe disease.
New psoriasis patient profile
Metabolomics could provide new statistical methods to help monitor psoriasis disease and progression.
Expense drivers for costliest psoriasis patients
Findings of a recent study challenge the notion that psoriasis patients may be generally healthy and only acquire expenses related to their medications or psoriasis.
Urologists who adopt EMRs cite many benefits, some risks
Thinking about adopting an electronic medical record system? You're not alone. According to a recent AUA survey, just 7% to 10% of urology practices are currently using EMR systems, but another 24% to 30% indicated that they are starting to make decisions on a system now.
Prostate Ca patients urged to consult a medical oncologist
New York--Men with prostate cancer are being urged to seek the advice of a medical oncologist in a new educational campaign launched by the Prostate Cancer Foundation.
Antiandrogen/castration may reduce death risk by 20%
New Orleans--Bicalutamide (Casodex), 50 mg, plus castration leads to an estimated 20% reduction in risk of prostate cancer death versus castration alone, according to results of a historical data analysis presented at the annual of the American Society of Clinical Oncology meeting here.


View Results